Potential drugs for beta cell regeneration discovered

At the April 2014 JDRF-GNF (Genomics Institute of the Novartis Research Foundation) meeting, Dr. Byran Laffitte described how GNF has the potential to identify the first disease altering therapy for T1D. He presented preclinical evidence that GNF has identified the first highly effective low molecular weight regulators of beta cell proliferation. Overall, GNF has identified […]

Progress on ViaCyte’s novel encapsulated cell therapy

In February, JDRF announced it is providing additional milestone-based funding for the continued development of ViaCyte’s VC-01™ encapsulated cell therapy product candidate for the treatment of T1D. JDRF will fund up to $7 million to help ensure a rapid transition of the project into the clinical phase of development once ViaCyte’s investigational new drug application […]

Creating a world without type 1 diabetes

We’re the plan to change the future type. JDRF research focuses on key therapies that hold significant promise in turning Type One into Type None, including: artificial pancreas, encapsulation, smart insulin, restoration, and prevention.

Broadening T1D R&D funding sources

Last year JDRF took a number of significant actions to broaden the resources available in the T1D research and development space – three of them are highlighted here. Each of these will help speed progress towards our research goals across our portfolio of research objectives to develop and deliver novel T1D therapies to patients. In […]

New JDRF-funded study will evaluate potential benefits of metformin for type 1 diabetes

A new JDRF-funded study will evaluate whether metformin—a drug commonly used to treat type 2 diabetes (T2D)—combined with standard insulin therapy could safely improve blood-glucose control in overweight children and adolescents with type 1 diabetes (T1D). For more than 50 years, metformin has proven safe and effective in helping to control blood-glucose levels in people […]

Inhaled insulin shows value in artificial pancreas study

Last September, results from a JDRF-funded study were announced by Sansum Diabetes Research Institute and JDRF. This study addresses one of the key limitations of early artificial pancreas systems – the challenge of mealtime dosing of insulin. This is because insulin delivered through the skin by a pump or injections works much slower than insulin […]